Zogenix Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 04, 2021 16:05 ET
|
Zogenix, Inc
FINTEPLA® net product sales of $21.4 million and total revenue of $22.6 million in the third quarter, representing quarter-over-quarter increases of 22% and 20%, respectivelySubmitted supplemental New...
Zogenix to Host Key Opinion Leader Webinar on Thymidine Kinase 2 Deficiency and MT-1621
November 01, 2021 08:00 ET
|
Zogenix, Inc
EMERYVILLE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will host a key opinion...
Zogenix to Release Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4
October 21, 2021 08:00 ET
|
Zogenix, Inc
EMERYVILLE, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced data that it will report its...
Zogenix Reports Granting of Inducement Awards
October 19, 2021 08:00 ET
|
Zogenix, Inc
EMERYVILLE, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of directors granted inducement awards to...
New FINTEPLA® (Fenfluramine) Data Show Long-Term Seizure Frequency Reductions in Patients with Lennox-Gastaut Syndrome (LGS)
September 30, 2021 08:00 ET
|
Zogenix, Inc
Median reduction in drop seizure frequency was 39.4% at 3 months (n= 227; p<0.0001) and 51.8% for patients assessed over months 10 to 12 (n=170; p<0.0001).A Supplemental New Drug Application...
Zogenix Submits Supplemental New Drug Application for FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome
September 28, 2021 08:00 ET
|
Zogenix, Inc
Supplemental New Drug Application (sNDA) submission is supported by existing clinical data, including positive data from Company’s Phase 3 trial, Study 1601, in which the primary endpoint was met with...
Zogenix Reports Granting of Inducement Awards
September 16, 2021 17:39 ET
|
Zogenix, Inc
EMERYVILLE, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of directors granted inducement awards to...
Zogenix Receives Orphan Drug Designation for FINTEPLA® (Fenfluramine) in Japan
August 26, 2021 08:00 ET
|
Zogenix, Inc
Zogenix plans to submit a new drug application (J-NDA) for FINTEPLA in Japan for the treatment of seizures associated with Dravet syndrome by year end.Dravet syndrome is a rare, life-long form of...
Zogenix Reports Granting of Inducement Awards
August 16, 2021 17:02 ET
|
Zogenix, Inc
EMERYVILLE, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of directors granted inducement awards to fourteen...
Zogenix Provides Corporate Update and Reports Second Quarter 2021 Financial Results
August 05, 2021 16:01 ET
|
Zogenix, Inc
Commercial launches of FINTEPLA® in the U.S. and Europe progressing strongly, with total net product sales of $17.5 million and total revenue of $18.8 million in the second quarter, representing...